FACE MAKE-UP BODY

VENUCEANE
TM

Thermus thermophilus

Function:
Reinforcement of the cutaneous barrier.
Improvement of skin moisture and
corneocyte cohesion.
Definition:
Biotechnological product obtained from the
culture of Thermus thermophilus.
Properties:
Stimulates production of the structural lipids
of the stratum corneum (ceramides).
Stimulates keratinocyte maturation.
Characteristics:
Preserves and reinforces the skin’s natural
physical and biochemical defences.
Particular signs:
Thermus thermophilus lives in deep-sea
water (2000 m depth, 75°C temperature,
200 bars pressure).
Origin:
Guaymas Basin (Gulf of California)
INCI name:
Thermus Thermophillus Ferment –
Glycerin

Applications:
Protective day creams, sun protection
products, make-up.

Formulation:
Water soluble. Add in the formula
between room temperature and 80°C
Recommended use level:
3-5%
Patent:
FR 2 821 086 - FR 3 004 351 -
WO 2014/170801 - WO 02/066668 -
EP 2 986 305 - EP 1 392 840

www.sederma.com
E-mail: sederma@sederma.fr
Copyright© 2007-2018 Sederma.
All rights reserved.
Part of Croda International Plc.
 CLAIM SUBSTANTIATION 05-2015

In vivo tests
Clinical study: Venuceane™ against placebo
15 Volunteers / daily application of a gel containing 3% VENUCEANE™ on the leg against placebo for 2 months / Measurement of TEWL after stratum corneum
stripping, and measurement of skin moisture by corneometry.

Change in TEWL: Measurement of skin Visualisation of corneocyte hydration by electronic

after treatment and moisture by corneometry microscopy after a 56-days of treatment
20 strippings
Increase of TEWL (%) Increase of moisture (%)
220 27
200 25
180 23
160
21
140
19
120

*
100 17

80 15
D0 D56 D0 D56 D56 D56+24H D56 D56+24H

Placebo Venuceane™ * significant p<0.05 / D56

Control Venuceane™

In vitro tests
Stimulation of the keratinocyte differentiation Improvement in lipid production
(maturation)
Visualisation of involucrin (a marker of keratinocyte differentiation) on Visualisation of lipid production on keratinocyte culture after 5 days incubation
keratinocyte culture (basal cells) by immunofluorescence. by HPTLC.
Ceramides
type 2

Control
Venuceane™

Glyco-ceramides Cholesterol Free Migration

Control 3% Venuceane™ fatty front
acids

Venuceane™ stimulates keratinocyte maturation and Venuceane™ stimulates the production of lipids
then improves the epidermis integrity. responsible for epidermal cohesion and structure.

Venuceane™ restores the quality of the cutaneous barrier and significantly reduces the water loss after induced lesion.
Venuceane™ can stimulate the endogenous mechanisms of prevention and repair (stimulation of keratinocyte differentiation and
increase of ceramide production).

Formulation
Reviving Spray with VENUCEANE™ Suggested formulation ref.:
SED 0503519-I
Part A .................................................................................................................% Glycerin 5.00
Sodium hydroxide 30% 0.20 Preservative qs
Potassium sorbate 0.10 Part D .................................................................................................................%
Deionised water qs 100 VENUCEANE™ (Sederma) 3.00
Part B .................................................................................................................% Part E .................................................................................................................%
Volpo CS 10 (Ceteareth-20, Croda) 1.50 Fragrance 0.10
Crodafos CS 20 Acid (Cetearyl Alcohol and Ceteth-20 3.00
Phosphate and Dicetyl Phosphate, Croda) Protocol:
Crodamol GTCC (Caprylic/Capric Triglycerides, Croda) 8.00 Heat Part A to 75°C. Melt Part C until dissolution, then add it to Part B. Heat Part (B+C)
Cyclomethicone 1.00 to 75°C in water-bath. Mix well. Pour Part A into Part (B+C) with Staro stirring (s=30%).
Part C .................................................................................................................% Homogenize carefully. Add Parts D and E at about 45°C. Homogenize well while cooling.

Non-warranty : This formulation has been subject to limited stability tests and has been shown to perform well. However formulators adopting this approach should ensure to their own satisfaction long term stability and functionality. It is good practice to conduct safety tests on all final
formulations prior to marketing. Suggested uses should not be taken as an inducement to infringe any existing patents.

Non-warranty: The information in this publication is believed to be accurate and is given in good faith, but no representation or warranty as to its completeness or accuracy
is made. Suggestions for uses or applications are only opinions. Users are responsible for determining the suitability of these products for their own particular purpose. No
representation or warranty, expressed or implied, is made with respect to information or products including, without limitation, warranties of merchantability, fitness for a
29 rue du Chemin Vert particular purpose, non-infringement of any third party patent or other intellectual property rights including, without limit, copyright, trademark and designs. Any trademarks
78612 Le Perray-en-Yvelines cedex France identified herein, unless otherwise noted, are trademarks of the Croda group of companies. ©2018 Sederma 03/18 PCS PO 012 V3 EN
Tel. : +33 (0)1 34 84 10 10 Reproduction of all or part of this document without the express prior written consent of Sederma is strictly prohibited.